Evidence map›Paper›PMID 37164513›Full record

Trial reportThe Lancet. Planetary health2023

Differential impact of dual-active ingredient long-lasting insecticidal nets on primary malaria vectors: a secondary analysis of a 3-year, single-blind, cluster-randomised controlled trial in rural Tanzania.

Nancy S Matowo, Manisha A Kulkarni, Louisa A Messenger, Mohamed Jumanne, Jackline Martin, Elizabeth Mallya, Eliud Lukole, Jacklin F Mosha, Oliva Moshi, Boniface Shirima and 5 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Planetary health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Comparative malaria impact of chlorfenapyr-α-cypermethrin netsCurrent research in parasitology & vector-borne diseases · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Nancy S MatowoDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: nancy.matowo@lshtm.ac.uk.
Manisha A KulkarniSchool of Epidemiology and Public Health, University of Ottawa, OT, Canada.
Louisa A MessengerDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK; Department of Environmental and Occupational Health, School of Public Health, University of Nevada, Las Vegas, NV, USA.
Mohamed JumanneDepartment of Parasitology, National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania.
Jackline MartinDepartment of Parasitology, National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania.
Elizabeth MallyaKilimanjaro Christian Medical University College, Moshi, Tanzania.
Eliud LukoleDepartment of Parasitology, National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania.
Jacklin F MoshaDepartment of Parasitology, National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania.
Oliva MoshiKilimanjaro Christian Medical University College, Moshi, Tanzania.
Boniface ShirimaKilimanjaro Christian Medical University College, Moshi, Tanzania.
Robert KaayaKilimanjaro Christian Medical University College, Moshi, Tanzania.
Mark RowlandDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.
Alphaxard ManjuranoDepartment of Parasitology, National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania.
Franklin W MoshaKilimanjaro Christian Medical University College, Moshi, Tanzania.
Natacha ProtopopoffDepartment of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.
Kilimanjaro Christian Medical Centre · TZNational Institute for Medical Research · TZLondon School of Hygiene & Tropical Medicine · GBOttawa Public Health · CA

Funding

Medical Research Council MR/R006040/1Wellcome Trust
6 · The paper itself

Abstract

backgroundGains in malaria control are threatened by widespread pyrethroid resistance in malaria vectors across sub-Saharan Africa. New long-lasting insecticidal nets (LLINs) containing two active ingredients (dual active-ingredient LLINs) have been developed to interrupt transmission in areas of pyrethroid resistance. We aimed to evaluate the effectiveness of three dual active-ingredient LLINs compared with standard pyrethroid LLINs against pyrethroid-resistant malaria vectors in rural Tanzania.

methodsIn this study, we did a secondary analysis of entomological data from a four-group, 3 year, single-blind, cluster-randomised controlled trial carried out between Feb 18, 2019, and Dec 6, 2021. We conducted quarterly indoor mosquito collections using the Centers for Disease Control and Prevention light trap, in eight houses in each of the 84 study clusters in the Misungwi district, northwestern Tanzania. Anopheles vectors were then tested for malaria parasites and identified at species level, to distinguish between sibling species of the Anopheles gambiae and Anopheles funestus groups, using molecular laboratory techniques. The primary outcomes were density of different malaria vector species measured as the number of female Anopheles collected per household per night, the entomological inoculation rate (EIR), an indicator of malaria transmission, and sporozoite rate. Entomological outcomes were assessed on the basis of intention to treat, and the effect of the three dual active-ingredient LLINs was compared with the standard pyrethroid LLINs at household level.

findingsDual active-ingredient LLINs had the greatest effect on Anopheles funestus sl, the most efficient vector in the study area, with comparatively weak effect on An arabiensis. An funestus density was 3∙1 per house per night in the pyrethroid LLIN group, 1∙2 in the chlorfenapyr pyrethroid LLIN group (adjusted density ratio [aDR]=0∙26, 95% CI 0∙17-0∙14, p<0∙0001), 1∙4 in the piperonyl-butoxide pyrethroid LLIN group (aDR=0∙49, 0∙32-0∙76, p=0∙0012), and 3∙0 in the pyriproxyfen pyrethroid LLIN group (aDR=0∙72, 0∙47-1∙11, p=0∙15). Malaria transmission intensity was also significantly lower in the chlorfenapyr pyrethroid group, with 0∙01 versus 0∙06 infective bites per household per night in the pyrethroid LLIN group (aDR=0∙21, 0∙14-0∙33, p<0∙0001). Ecological niche models indicated that vector-species distribution was stable following LLIN intervention despite the reductions observed in An funestus sl density.

interpretationChlorfenapyr pyrethroid LLINs were the most effective intervention against the main malaria vector An funestus sl over 3 years of community use, whereas the effect of piperonyl-butoxide pyrethroid LLIN was sustained for 2 years. The other vector, An arabiensis, was not controlled by any of the dual active-ingredient LLINs. Additional vector control tools and strategies targeted to locally prevalent vector species evading dual active-ingredient LLINs should be deployed to further reduce malaria transmission and achieve elimination.

fundingThe Department for International Development, UK Medical Research Council, Wellcome Trust, the Department of Health and Social Care, and The Bill & Melinda Gates Foundation via the Innovative Vector Control Consortium.

Indexed as

AnophelesInsecticidesInsecticide-Treated BednetsMalariaPyrethrinsAnimalsFemaleHumansMosquito ControlMosquito VectorsPiperonyl ButoxideSingle-Blind MethodTanzaniaUnited StateschlorfenapyrInsecticidesPiperonyl ButoxidePyrethrins

Identifiers

PMID37164513
PMCPMC10186178
OpenAlexW4376132479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.